

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/031,180	08/05/2002	Alistair Dixon	A0000096-01-SMH	2579
759	90 04/07/2004		EXAMINER	
Suzanne M Harvey			HUI, SAN MING R	
Warner Lambert Company 2800 Plymouth Road			ART UNIT	PAPER NUMBER
Ann Arbor, MI			1617	

DATE MAILED: 04/07/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		10/031,180	DIXON ET AL.				
		Examiner	Art Unit				
	ŕ	San-ming Hui	1617				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period fo		OD DEDLY IO OFT TO EVENE	MONTH/ON FROM				
THE External	ORTENED STATUTORY PERIOD FOR MAILING DATE OF THIS COMMUNI Insions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this common period for reply specified above is less than thirty (3) period for reply is specified above, the maximum stare to reply within the set or extended period for reply reply received by the Office later than three months are departed term adjustment. See 37 CFR 1.704(b).	CATION. of 37 CFR 1.136(a). In no event, however, mailunication. 0) days, a reply within the statutory minimum of attutory period will apply and will expire SIX (6) Nowill, by statute, cause the application to become	v a reply be timely filed thirty (30) days will be considered timely. MONTHS from the mailing date of this communication.				
Status							
1)	Responsive to communication(s) file	ed on		ļ			
2a) <u></u>	This action is FINAL .	2b) This action is non-final.					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
5) 6) 7)	Claim(s) <u>1-54</u> is/are pending in the at 4a) Of the above claim(s) is/are Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>1-54</u> are subject to restricti	re withdrawn from consideration.					
	ion Papers						
,	The specification is objected to by the		to but he Everyiner				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
			ring(s) is objected to. See 37 CFR 1.121(d).				
11)	The oath or declaration is objected to						
Priority	under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachme	nt(s)	<u> </u>					
=	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (I	, _	ew Summary (PTO-413) No(s)/Mail Date				
3) 🔲 Info	ce of Draftsperson's Patent Drawing Review (i rmation Disclosure Statement(s) (PTO-1449 of er No(s)/Mail Date		of Informal Patent Application (PTO-152)				

Art Unit: 1617

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-25 and 52-53, drawn to a method of treating chronic pain by employing compounds with formula I, which is a benzamide.

Group II, claim(s) 26-35, 54(in part), 38-43, drawn to a method of treating chronic pain by employing compounds with formula I(A), wherein Z is carboxylic acid.

Group III, claim(s) 26-35, 54(in part), 36-37, drawn to a method of treating chronic pain by employing compounds with formula I(A), wherein Z is a tetrazoyl.

Group IV, claim(s) 26-35, 54(in part), 44-47, drawn to a method of treating chronic pain by employing compounds with formula I(A), wherein Z is $C(O)NR_6R_7$.

Group V claim(s) 26-35, 54(in part), 48-51, drawn to a method of treating chronic pain by employing compounds with formula I(A), wherein Z is an alcohol.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the inventions are directed to the employment of compounds with distinct structures and lack of a special technical feature. Thus, they do not represent a single general inventive concept.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Art Unit: 1617

Compounds with various moieties as identified above employed in the method of treating chronic pain.

Applicant is required, in reply to this action, to elect a single species (i.e., one single compound recited in the claims) to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

1-25 and 52-53, drawn to a benzamide compound

26-35, 54(in part), 38-43, drawn to a benzoic acid

26-35, 54(in part), 36-37, drawn to a tetrazole compound

26-35, 54(in part), 44-47, drawn to a compound which Z is C(O)NR₆R₇

26-35, 54(in part), 48-51, drawn to a benzyl alcohol

The following claim(s) are generic: 1-54.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: compounds in each group represent a variety of structurally different compounds evidenced by the different substituents, region-isomers, etc.

Art Unit: 1617

Because the above restriction/election requirement is complex, a telephone call to applicant's agent to request an oral election was not made. See M.P.E.P. Sec. 812.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (703) 305-1002. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

San-ming Hui

Patent Examiner

Art Unit 1617